

Figure 7A: Survival of RIP1-Tag5 mice (weeks)

Untreated	25.7
Untreated	27
Untreated	27.1
Untreated	27.3
Untreated	27.4
Untreated	27.9
Untreated	29.6
Untreated	30
Untreated	30
Untreated	30.1
Untreated	30.4
Untreated	30.4
Untreated	31
Untreated	26.6
Untreated	26.6
Untreated	26.7
Untreated	26.7
Untreated	26.7
Untreated	26.9
Untreated	27.3
Untreated	28.1
Untreated	28.4
Untreated	28.6
Untreated	29.4

TNF-CSG 5 ug	33.6
TNF-CSG 5 ug	29.9
TNF-CSG 5 ug	32.6
TNF-CSG 5 ug	32.7
TNF-CSG 5 ug	32.3
TNF-CSG 5 ug	30.7
TNF-CSG 5 ug	29.9
TNF-CSG 5 ug	31.9
TNF-CSG 5 ug	28.4
TNF-CSG 5 ug	26.4
TNF-CSG 5 ug	29.7
TNF-CSG 5 ug	30.7
TNF-CSG 5 ug	30.3
TNF-CSG 5 ug	31.7
TNF-CSG 5 ug	35.4
TNF-CSG 5 ug	36

Comparison of Survival Curves

Log-rank (Mantel-Cox) test		
Chi square	14.23	
df	1	
P value	0.0002	
P value summary	***	
sig different?	Yes	
Gehan-Breslow-Wilcoxon test		
Chi square	11.42	
df	1	
P value	0.0007	
P value summary	***	
sig different?	Yes	
Median survival		
Untreated	28.1	
TNF-CSG5 ug	31.2	
Ratio (and its reciprocal)	0.9006	1.11
95% CI of ratio	0.4853 to 1.672	0.5983 to 2.061
Hazard Ratio (Mantel-Haenszel)		
A/B	B/A	
Ratio (and its reciprocal)	3.837	0.2606
95% CI of ratio	1.908 to 7.716	0.1296 to 0.5242

Hazard Ratio (logrank)	A/B	B/A
Ratio (and its reciprocal)	2.732	0.366
95% CI of ratio	1.477 to 5.055	0.1978 to 0.6771

Figure 7B: Survival of 4T1 tumour-bearing mice (days)

Untreated	16	TNF CSG 2 ug	22
Untreated	18	TNF CSG 2 ug	23
Untreated	18	TNF CSG 2 ug	23
Untreated	18	TNF CSG 2 ug	25
Untreated	19	TNF CSG 2 ug	26
Untreated	19		
Untreated	20		

Comparison of Survival Curves		
Log-rank (Mantel-Cox) test		
Chi square	10.83	
df	1	
P value	0.001	
P value summary	**	
Are the survival curves sig different?	Yes	
Gehan-Breslow-Wilcoxon test		
Chi square	8.895	
df	1	
P value	0.0029	
P value summary	**	
Are the survival curves sig different?	Yes	
Median survival		
Untreated	18	
TNF-CSG	23	
Ratio (and its reciprocal)	0.7826	1.278
95% CI of ratio	0.2484 to 2.466	0.4055 to 4.026
Hazard Ratio (Mantel-Haenszel)	A/B	B/A
Ratio (and its reciprocal)	16.48	0.06067
95% CI of ratio	3.105 to 87.48	0.01143 to 0.3221
Hazard Ratio (logrank)	A/B	B/A
Ratio (and its reciprocal)	3.957	0.2527
95% CI of ratio	1.092 to 14.34	0.06973 to 0.9161

Figure 7C: tumour volume

Untreated	CSG	TNF-CSG 2 ug
386.5375	486.5255	375.17
247.009	318.3236	158.3839
443.576	381.8561	91.39235
332.82	227.8194	66.67699
690.9705	234.4322	69.02592
	648	247.45

	433.5	364.5
	281.75	100
	368	100
	379.75	171.5
		245

One-way ANOVA nonparametric multiple comparison

Kruskal-Wallis test

Number of families	1					
Number of comparisons	3					
Alpha	0.05					
Dunn's multiple comparisons test	Mean rank diff.	Significant?	Summary	Adjusted P Value		
Untreated 5 vs. CSG	2.1	No	ns	>0.9999		
Untreated 5 vs. TNF-CSG	11.56	Yes	*	0.0152		
CSG vs. TNF-CSG	9.464	Yes	*	0.0139		
Test details	Mean rank 1	Mean rank 2	Mean rank diff.	n1	n2	
Untreated 5 vs. CSG	19.2	17.1	2.1	5	10	
Untreated 5 vs. TNF-CSG	19.2	7.636	11.56	5	11	
CSG vs. TNF-CSG	17.1	7.636	9.464	10	11	

Figure 7D: FACS analysis of granzyme B cytotoxic T cells and regulatory CD4 T cells

CD8 T cells granzyme B+

CSG	TNF-CSG 2 ug
0.55	15.2
2.47	16.8
1.62	22.1
5.65	13.2
0.28	29

CD4 T cells granzyme B+

CSG	TNF-CSG 2 ug
2.83	3.92
0.633	3.1
0.526	2.74
1.79	2.89
1.19	2.04

Unpaired t-test

Table Analyzed	CD8 GranzymB
Column B	TNF-CSG 2 ug
vs.	vs.
Column A	CSG
Unpaired t test	
P value	0.0005
P value summary	***
Significantly different (P < 0.05)?	Yes
One- or two-tailed P value?	Two-tailed
t, df	t=5.701 df=8

Table Analyze	CD4 GranzymB
Column B	TNF-CSG 2 ug
vs.	vs.
Column A	CSG
Unpaired t test	
P value	0.0181
P value summary	*
Significantly different (P < 0.05)?	Yes
One- or two-tai	Two-tailed
t, df	t=2.963 df=8

CD4 T cells FoxP3+

CSG	TNF-CSG 2 ug
13.1	12.7
15.9	2.17
11.1	10.3
9.73	10.3
12.4	11.9

Unpaired t-test

Table Analyzed	CD4: CD25+ FOXP3+	
Column B	TNF-CSG 2 ug	
vs.	vs.	
Column A	CSG	
Unpaired t test		
P value	0.2045	
P value summary	ns	
Significantly different (P < 0.05)?	No	
One- or two-tailed P value	Two-tailed	
t, df	t=1.382 df=8	